Treatment of Fragile X Syndrome with cannabidiol
US11779549B2 · kind B2 · utility
1Cited by
17References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2022 |
| Grant date | Oct 10, 2023 |
| Priority date | — |
| Expiry date | Aug 24, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.